Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated.
Scott
Daniel A
DA
Wyeth Vaccines Research, 401 N. Middletown Road, Pearl River, NY 10965, USA.
Komjathy
Steven F
SF
Hu
Branda T
BT
Baker
Sherryl
S
Supan
Lois A
LA
Monahan
Carol A
CA
Gruber
William
W
Siber
George R
GR
Lockhart
Stephen P
SP
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006262:Health; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000276:immunology*; D022242:Pneumococcal Vaccines / Q000276:immunology*
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines